IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Zhou et al.

Serial No. 10/533,337

Filed: October 24, 2003

For: PIPERIDINYL CYCLOPENTYL ARYL BENZYLAMIDE

Art Unit:

Examiner:

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

ACTIVITY

MODULATORS OF CHEMOKINE RECEPTOR

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

Sir:

- 1. In compliance with 37 C.F.R. 1.97, submitted on the attached form herewith is a list of patents, publications or other information which are requested to be made of record in this application. This Information Disclosure Statement is not an admission that any patent, publication or other information referred to herein is "prior art" for this invention. In accordance with 37 C.F.R. 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. 1.56(b).
- 2. In accordance with 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.
- 3. Applicants respectfully request that the Examiner initial the attached form after reviewing the pertinence of each reference.
- 4. Pursuant to 37 C.F.R. 1.98 (a)(2)(ii), copies of each cited U.S. patent and each U.S. patent application publication are not enclosed herewith.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on the date appearing below.

MERCK & CO., INC.

RELATED APPLICATION

INFORMATION DISCLOSURE STATEMENT

5. Pursuant to 37 C.F.R. 1.98(d), copies of references listed on the attached form that were submitted to or cited by the Office in a related application upon which the instant application relies for an earlier filing date under 35 U.S.C. 120 are not enclosed. Related application(s) in which references were submitted to or cited by the Office are as follows:

4 Jan 1

	U. S. SERIAL NUMBER	FILING DATE	MERCK CASE			
If +b	nis is inconvenient, additional copies will be submitted upon request	<u></u>				
		•				
	6. In accordance with 37 C.F.R. 1.97, (check one)					
	the attached information is filed within three months of the filing da	te of the captioned case.				
\checkmark	the attached information is filed more than three months after the f Office Action on the merits.	iling date but prior to the m	nailing of a first			
	the attached information is filed before the mailing of a first Office a examination under §1.114.	action after the filing of a re	equest for continued			
	the attached information is being filed more than three months after the filing date and after the mailing of a first Office Action on the merits, but before the mailing date of a Final Action, Notice of Allowance, or an action that otherwise closes prosecution in the application. The enclosed authorization is therefore given to charge Deposit Account No. 13-2755 for the fee required under 37 C.F.R. 1.17(p).					
	each item of information contained in this Information Disclosure S from a foreign patent office in a counterpart foreign application not Statement.					
	each item of information contained in the information disclosure state a foreign patent office in a counterpart application and this communication of the designated in §1.56(c) more than thirty days prior to the filing of the	nication was not received	by any individual			
	no item of information contained in this Information Disclosure State foreign patent office in a counterpart foreign application, and, to the after making reasonable inquiry, was known to any individual designments prior to the filing of this Statement.	e knowledge of the person	signing the certification			

By: David A. Rubin Attorney For Applicant(s) Reg. No. 40,314 MERCK & CO., INC. Patent Dept., RY60-30 P.O. Box 2000 Rahway, N.J. 07065-0907 (732)594-2675 Date: December 30, 2005

Respectfully submitted,

Substitute for form 1449A/PTO				COMPLETE IF KNOWN		
INFORMATION DISCLOSURE				Application Number	10/533,337	
STATEMENT BY APPLICANT			DI ICANT	Filing Date	October 24, 2003	
			PLICANI	First Named Inventor	Zhou et al.	OIPE
				Group Art Unit	7	82
(use as many sheets as necessary)			ecessary)	Examiner Name	PA	JAN 0 3 700K
eet	1	of	2	Attorney Docket Number	21056P	& TRANSMAN

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.	U.S. Patent Document	Kind Code (if known)		Date of Publication of Cited Document MM-DD-YYYY	
		US2002/0049222		YANG et al.	04/25/2002	
			\bot			
			\bot			
			\bot			
			\bot			
			\perp			
			\bot			
				·		
	L					

	FOREIGN PATENT DOCUMENTS						
		Foreign Patent Document			Date of Public	Date of Publication of	
Examiner Initials*	Cite No.	Office	Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	
	ļ						
	ļ						
	ļ						
-		+ -			3.44		
	ļ	 					
Examin	er				Date		
Signatu	re				Considered		

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

hatituda far far — 1440R/DTO			COMPLETE IF KNOWN		
	DIS	CLOSURE	Application Number	10/533,337	
TEA TEIDA AIDAITE IDAZ	A D	DI ICANT	Filing Date	October 24, 2003	
IAIEMENI BY	AP	PLICANI	First Named Inventor	Zhou et al.	
		,	Group Art Unit		
(use as many sheets	as n	ecessary)	Examiner Name		
2	of	2	Attorney Docket Number	21056P	
	TATEMENT BY	NFORMATION DISC TATEMENT BY AP (use as many sheets as n	TATEMENT BY APPLICANT (use as many sheets as necessary)	TATEMENT BY APPLICANT (use as many sheets as necessary) Application Number Filing Date First Named Inventor Group Art Unit Examiner Name	

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.			
		•			

	Date Considered
--	--------------------